Dermata's Xyngari showed significant acne improvement in Phase 3 results. A second pivotal trial is set for the second half ...

The study evaluates 20 years of the US Food and Drug Administration (FDA) Adverse Event Reporting System data.

After new US Food and Drug Administration testing of acne products containing benzoyl peroxide, the agency determined that a small number of products should be recalled for possible benzene ...

A limited amount of retail products containing benzoyl peroxide have been voluntarily recalled after testing for possible benzene contamination.

That could include probiotics, both topical and oral. Two recent reviews of studies investigating this possibility suggest ...

Valisure, an independent quality advocate, filed a citizen petition claiming to have detected elevated levels of benzene in ...

Dermata Therapeutics shares jumped more than 50% in early trading Thursday after the biotechnology company said its Xyngari once-weekly, topical product candidate for the treatment of ...

Dermata Therapeutics (DRMA) announced positive topline results from the company’s first pivotal Phase 3 trial of xyngari, a novel, once-weekly, ...

Shares of Dermata Therapeutics, Inc. (Nasdaq: DRMA) climbed 60% following the announcement of successful Phase 3 trial results for their acne treatment, XYNGARI, ...

After nine months of work, we’ve crowned 31 new skin-care picks (plus plenty of sunscreens). Now, some of our favorites are ...

The Company claims the sponge powder exfoliates the skin, promotes collagen production, and opens closed comedones.